Oxaliplatin - In operable colorectal cancer

被引:5
作者
Keam, SJ [1 ]
Dunn, CJ [1 ]
Figgitt, DP [1 ]
机构
[1] Adis Int Ltd, Auckland 1311, New Zealand
关键词
D O I
10.2165/00003495-200565010-00005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Oxaliplatin is available in numerous countries for the treatment of metastatic colorectal cancer (in conjunction with fluoropyrimidine therapy). The activity of oxaliplatin in advanced disease has led to investigation of its potential in operable disease. The addition of oxaliplatin to adjuvant therapy with fluorouracil and folinic acid (FOLFOX4 regimen) is associated with a significantly greater disease-free survival at 3 years (78% vs 73%; p = 0.002), according to results of the MOSAIC (Multicenter International Study of Oxaliplatin/5FU/Leucovorin [folinic acid] in the Adjuvant Treatment of Colon Cancer) trial, a study in 2246 patients with stage II or III colon cancer. In addition, a 23% reduction in the risk of disease recurrence after surgery was seen with FOLFOX4 compared with fluorouracil/folinic acid in the MOSAIC trial. Results from several phase I/II studies suggest that the addition of oxaliplatin to preoperative radiochemotherapy may be of benefit in patients with locally advanced lower rectal cancer in terms of disease downstaging and sphincter preservation. Oxaliplatin was generally well tolerated in the MOSAIC trial and neuro- and myelotoxicity with FOLFOX4 were manageable.
引用
收藏
页码:89 / 96
页数:8
相关论文
共 40 条
[1]  
Alonso V, 2004, J CLIN ONCOL, V22, p271S
[2]   Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].
Andre, T ;
Boni, C ;
Mounedji-Boudiaf, L ;
Navarro, M ;
Tabernero, J ;
Hickish, T ;
Topham, C ;
Zaninelli, M ;
Clingan, P ;
Bridgewater, J ;
Tabah-Fisch, I ;
de Gramont, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351
[3]  
ASCHELE C, 2002, P AN M AM SOC CLIN, V21, P132
[4]  
Avallone A, 2004, J CLIN ONCOL, V22, p865S
[5]   American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer [J].
Benson, AB ;
Schrag, D ;
Somerfield, MR ;
Cohen, AM ;
Figueredo, AT ;
Flynn, PJ ;
Krzyzanowska, MK ;
Maroun, J ;
McAllister, P ;
Van Cutsem, E ;
Brouwers, M ;
Charette, M ;
Haller, DG .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3408-3419
[6]  
Blackstock A. William, 2002, International Journal of Molecular Medicine, V10, pS68
[7]  
BLACKSTOCK AW, 2003, P AACR, V44, pS27
[8]   Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences [J].
Boisdron-Celle, M ;
Craipeau, MC ;
Brienza, S ;
Delva, R ;
Guérin-Meyer, V ;
Cvitkovic, E ;
Gamelin, E .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2002, 49 (03) :235-243
[9]  
CASADO E, 2003, P AN M AM SOC CLIN, V22, P334
[10]   Adjuvant therapy in colon cancer: current status and future directions cancer [J].
Chau, I ;
Cunningham, D .
CANCER TREATMENT REVIEWS, 2002, 28 (05) :223-236